Drug Delivery Spin-Off Adds OTC
This article was originally published in Start Up
Executive Summary
Vectura, focused on pulmonary drug delivery, has created a spin off which assembles the oral and dermal technologies it had already de-prioritized, with two enabling technologies from Unilever. PharmaKodex Ltd. will develop OTC drugs as a fast route to market, followed by Rx products using the same technologies.
You may also be interested in...
Trade Sales Trump IPOs, Even for Platforms
Europe's summertime flurry of private biotech sell-offs points to growing pragmatism among management and VCs, and still-poor valuations on the public markets. Firms which haven't already considered the trade sale opportunity should do so--even early-stage, pre-product platform groups.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.